Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause

@article{Unkila2013VaginalEO,
  title={Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause},
  author={Mikko Unkila and Seppo Juhani Kari and Emrah Yatkin and Risto A. S. Lammintausta},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={2013},
  volume={138},
  pages={107-115}
}
Ospemifene is a unique tissue-selective estrogen agonist/antagonist (also known as a selective estrogen receptor modulator [SERM]) with demonstrated efficacy in Phase 3 studies of postmenopausal women with vulvar and vaginal atrophy (VVA). This report describes preclinical studies on the effects of ospemifene in the ovariectomized (OVX) rat model of menopause. Ospemifene (10mg/kg/day) and the SERM comparator, raloxifene (10mg/kg/day) were administered for 2 weeks and both increased vaginal… 
Tissue selectivity of ospemifene: Pharmacologic profile and clinical implications
TLDR
Based on the preclinical evidence, ospemifene has beneficial estrogen-like effects on the vaginal epithelium, preliminary evidence to support a neutral endometrial profile, antiproliferative effects in breast, and estrogenic effects in bone.
Effects of ospemifene on vaginal epithelium of post-menopausal women
TLDR
In postmenopausal women affected by VVA, 1 month intake of ospemifene is associated with an increased maturation, and ERα expression of the vaginal mucosa, which may partially explain the improvement of symptoms of vaginal atrophy reported with this drug.
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence
TLDR
Available evidence indicates that ospemifene has unique effects on tissue, leading to a favorable long-term profile for the relief of vulvar and vaginal atrophy compared with other estrogen receptor agonists/antagonists with no short-term concerns about endometrial safety.
Effects of vaginal conjugated equine estrogens and ospemifene on the rat vaginal wall and lower urinary tract
TLDR
Unless contraindicated, the beneficial effects of vaginal CEE on the vaginal wall outweigh those of OS, and ospemifene alters vaginal epithelium in a unique way that is additive with local estrogen.
Ospemifene: A first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy
TLDR
The FDA approval of ospemifene is hailed as a significant milestone in postmenopausal women's health and a justification of the future clinical evaluation of oSpemifenes as a potential breast cancer chemopreventive agent, where several preclinical studies in different rodent breast cancer models strongly suggest oSPemifen is as effective as tamoxifen.
Eto , C Ospemifene versus Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
Relevance 57% of postmenopausal women suffer from female sexual dysfunction (FSD). Vulvovaginal atrophy (VVA) is a condition that impacts up to 60% of the growing postmenopausal female population,
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
TLDR
Results of Phase III clinical trials showed that ospemifene significantly improved the vaginal maturation index, decreased vaginal pH, and decreased severity of the self-identified most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo.
Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use
TLDR
Ospemifene is an approved oral option for postmenopausal women seeking treatment for VVA with bothersome dyspareunia, particularly for those who have tried and failed over-the-counter options or do not want vaginal therapies.
Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause
TLDR
Preclinical and clinical data describing the safety and efficacy of ospemifene for vaginal dryness and dyspareunia due to VVA and its effects on sexual function were reviewed.
Ospemifene: a safe treatment of vaginal atrophy
3934 Abstract. – OBJECTIVE: Vaginal atrophy is a chronic, progressive medical condition that affects fifty percent of postmenopausal women, causing symptoms like dyspareunia, vaginal dryness, and
...
1
2
3
...

References

SHOWING 1-10 OF 42 REFERENCES
Ospemifene use in postmenopausal women
TLDR
The recently released results from a pivotal Phase III study in postmenopausal women demonstrated statistically significant improvements of ospemifene 60 mg/day in symptoms of vulvar and vaginal atrophy over the use of non-hormonal vaginal lubricant.
Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women
TLDR
Ospemifene, at the dose of 90 mg/day, was more estrogenic than raloxifenes, as shown by changes in serum follicle-stimulating hormone and sex hormone-binding globulin levels.
Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice
TLDR
The results of these two studies suggest that women taking ospemifene for osteoporosis and/or urogenital atrophy may further benefit from ospEMifene's breast cancer chemopreventive effects.
Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy
TLDR
In this study, once-daily oral ospemifene 60 mg was effective for the treatment of vulvar and vaginal atrophy in postmenopausal women with dyspareunia.
Molecular analysis of the vaginal response to estrogens in the ovariectomized rat and postmenopausal woman
TLDR
At the transcriptional level, there is evidence of significant overlap of the effects of estrogen treatment between the OVX rat and human VA samples.
Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor &bgr; and androgen receptor in rats
TLDR
Lasofoxifene stimulated vaginal mucus formation without causing cell proliferation in the rat reproductive tract, and may be due to the increased vaginal estrogen receptor and androgen receptor levels.
Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats1.
TLDR
The bone-sparing, antitumor, and cholesterol-lowering effects of FC1271a combined with a low uterotropic activity and lack of liver toxicity indicate that FC 1271a could be an important alternative in planning antiosteoporosis therapy for estrogen deficiency.
Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.
TLDR
Bazedoxifene acetate represents a promising new treatment for osteoporosis, with a potential for less uterine and vasomotor effects than selective estrogen receptor modulators currently used in clinical practice.
Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina
TLDR
DHEA exerts both androgenic and estrogenic effects on the vaginal mucosa, thus providing a more physiological replacement therapy, and particularly interesting effects of DHEA on the three layers of the vaginal wall, namely a highly mucified epithelium, an increased muscularis thickness and increased collagen fiber compactness in the lamina propria.
Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study
TLDR
Ospemifene was shown to be effective and well tolerated for the treatment of the symptoms of vaginal dryness and dyspareunia associated with vulvovaginal atrophy over and above the use of provided lubricants.
...
1
2
3
4
5
...